These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24975498)

  • 1. T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee.
    Callendret B; Eccleston HB; Hall S; Satterfield W; Capone S; Folgori A; Cortese R; Nicosia A; Walker CM
    Hepatology; 2014 Nov; 60(5):1531-40. PubMed ID: 24975498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral.
    Callendret B; Eccleston HB; Satterfield W; Capone S; Folgori A; Cortese R; Nicosia A; Walker CM
    Hepatology; 2016 May; 63(5):1442-54. PubMed ID: 26513111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Dose Vaccination with a Hepatotropic Adeno-associated Virus Efficiently Localizes T Cell Immunity in the Liver with the Potential To Confer Rapid Protection against Hepatitis C Virus.
    Mekonnen ZA; Grubor-Bauk B; English K; Leung P; Masavuli MG; Shrestha AC; Bertolino P; Bowen DG; Lloyd AR; Gowans EJ; Wijesundara DK
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus.
    Hartlage AS; Walker CM; Kapoor A
    J Virol; 2020 May; 94(10):. PubMed ID: 32102885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of HCV-specific Patr class II restricted CD4+ T cell responses in an acutely infected chimpanzee.
    Woollard DJ; Grakoui A; Shoukry NH; Murthy KK; Campbell KJ; Walker CM
    Hepatology; 2003 Nov; 38(5):1297-306. PubMed ID: 14578870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
    Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
    J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broadening CD4
    Filskov J; Mikkelsen M; Hansen PR; Christensen JP; Thomsen AR; Andersen P; Bukh J; Agger EM
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28446674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing Hepatitis C Virus-Specific CD4
    Hartnell F; Esposito I; Swadling L; Brown A; Phetsouphanh C; de Lara C; Gentile C; Turner B; Dorrell L; Capone S; Folgori A; Barnes E; Klenerman P
    Hepatology; 2020 Nov; 72(5):1541-1555. PubMed ID: 32012325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections.
    Shoukry NH; Sidney J; Sette A; Walker CM
    J Immunol; 2004 Jan; 172(1):483-92. PubMed ID: 14688358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCV persistence and immune evasion in the absence of memory T cell help.
    Grakoui A; Shoukry NH; Woollard DJ; Han JH; Hanson HL; Ghrayeb J; Murthy KK; Rice CM; Walker CM
    Science; 2003 Oct; 302(5645):659-62. PubMed ID: 14576438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signatures of protective memory immune responses during hepatitis C virus reinfection.
    Abdel-Hakeem MS; Bédard N; Murphy D; Bruneau J; Shoukry NH
    Gastroenterology; 2014 Oct; 147(4):870-881.e8. PubMed ID: 25038432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
    Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
    Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-vectored T cell vaccine for hepacivirus shows reduced effectiveness against a CD8 T cell escape variant in rats.
    Hartlage AS; Dravid P; Walker CM; Kapoor A
    PLoS Pathog; 2021 Mar; 17(3):e1009391. PubMed ID: 33735321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice.
    Holmström F; Pasetto A; Nähr V; Brass A; Kriegs M; Hildt E; Broderick KE; Chen M; Ahlén G; Frelin L
    J Immunol; 2013 Feb; 190(3):1113-24. PubMed ID: 23284053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV.
    Caetano J; Martinho A; Paiva A; Pais B; Valente C; Luxo C
    J Virol; 2008 Aug; 82(15):7567-77. PubMed ID: 18480446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-B*27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope.
    Nitschke K; Barriga A; Schmidt J; Timm J; Viazov S; Kuntzen T; Kim AY; Lauer GM; Allen TM; Gaudieri S; Rauch A; Lange CM; Sarrazin C; Eiermann T; Sidney J; Sette A; Thimme R; López D; Neumann-Haefelin C
    J Hepatol; 2014 Jan; 60(1):22-9. PubMed ID: 23978718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy.
    Martin B; Hennecke N; Lohmann V; Kayser A; Neumann-Haefelin C; Kukolj G; Böcher WO; Thimme R
    J Hepatol; 2014 Sep; 61(3):538-43. PubMed ID: 24905492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses.
    Pillai V; Lee WM; Thiele DL; Karandikar NJ
    J Viral Hepat; 2007 May; 14(5):318-29. PubMed ID: 17439521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus-specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells.
    Roque-Cuéllar MC; Sánchez B; García-Lozano JR; Praena-Fernández JM; Márquez-Galán JL; Núñez-Roldán A; Aguilar-Reina J
    Liver Int; 2014 Jul; 34(6):e80-8. PubMed ID: 24127783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.